Bacteremic pneumococcal pneumonia

clinical outcomes and preliminary results of inflammatory response

J. M. Bordon, R. Fernandez-Botran, T. L. Wiemken, P. Peyrani, S. M. Uriarte, F. W. Arnold, L. Rodriquez-Hernandez, M. J. Rane, R. R. Kelley, L. E. Binford, S. Uppatla, R. Cavallazzi, F. Blasi, S. Aliberti, Marcos Restrepo, S. Fazeli, A. Mathur, M. Rahmani, K. Ayesu, J. Ramirez

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP. Methods: This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1rα, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups. Results: From 833 pneumococcal CAP patients, 394 patients (47 %) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 % CI 0.69–0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 % CI 1.06–2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p 

Original languageEnglish (US)
Pages (from-to)729-738
Number of pages10
JournalInfection
Volume43
Issue number6
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Pneumococcal Pneumonia
Pneumonia
Length of Stay
Hospital Mortality
Bacteremia
Brain Natriuretic Peptide
Interleukins
Calcitonin
Interleukin-8
Proportional Hazards Models
Interleukin-10
C-Reactive Protein
Interleukin-6
Patient Care
Hospitalization
Neutrophils
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Biomarkers
Outcome Assessment (Health Care)

Keywords

  • Biomarkers
  • Chemokines
  • Community-acquired pneumonia
  • Cytokines
  • Inflammatory response
  • Mortality
  • Neutrophil functional responses
  • Outcome
  • Pneumococcal bacteremia
  • Pneumonia severity
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Bordon, J. M., Fernandez-Botran, R., Wiemken, T. L., Peyrani, P., Uriarte, S. M., Arnold, F. W., ... Ramirez, J. (2015). Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection, 43(6), 729-738. https://doi.org/10.1007/s15010-015-0837-z

Bacteremic pneumococcal pneumonia : clinical outcomes and preliminary results of inflammatory response. / Bordon, J. M.; Fernandez-Botran, R.; Wiemken, T. L.; Peyrani, P.; Uriarte, S. M.; Arnold, F. W.; Rodriquez-Hernandez, L.; Rane, M. J.; Kelley, R. R.; Binford, L. E.; Uppatla, S.; Cavallazzi, R.; Blasi, F.; Aliberti, S.; Restrepo, Marcos; Fazeli, S.; Mathur, A.; Rahmani, M.; Ayesu, K.; Ramirez, J.

In: Infection, Vol. 43, No. 6, 01.12.2015, p. 729-738.

Research output: Contribution to journalArticle

Bordon, JM, Fernandez-Botran, R, Wiemken, TL, Peyrani, P, Uriarte, SM, Arnold, FW, Rodriquez-Hernandez, L, Rane, MJ, Kelley, RR, Binford, LE, Uppatla, S, Cavallazzi, R, Blasi, F, Aliberti, S, Restrepo, M, Fazeli, S, Mathur, A, Rahmani, M, Ayesu, K & Ramirez, J 2015, 'Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response', Infection, vol. 43, no. 6, pp. 729-738. https://doi.org/10.1007/s15010-015-0837-z
Bordon JM, Fernandez-Botran R, Wiemken TL, Peyrani P, Uriarte SM, Arnold FW et al. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection. 2015 Dec 1;43(6):729-738. https://doi.org/10.1007/s15010-015-0837-z
Bordon, J. M. ; Fernandez-Botran, R. ; Wiemken, T. L. ; Peyrani, P. ; Uriarte, S. M. ; Arnold, F. W. ; Rodriquez-Hernandez, L. ; Rane, M. J. ; Kelley, R. R. ; Binford, L. E. ; Uppatla, S. ; Cavallazzi, R. ; Blasi, F. ; Aliberti, S. ; Restrepo, Marcos ; Fazeli, S. ; Mathur, A. ; Rahmani, M. ; Ayesu, K. ; Ramirez, J. / Bacteremic pneumococcal pneumonia : clinical outcomes and preliminary results of inflammatory response. In: Infection. 2015 ; Vol. 43, No. 6. pp. 729-738.
@article{e2293eb9ccf8414a974a1fe100951fdd,
title = "Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response",
abstract = "Purpose: Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP. Methods: This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1rα, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups. Results: From 833 pneumococcal CAP patients, 394 patients (47 {\%}) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 {\%} CI 0.69–0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 {\%} CI 1.06–2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p ",
keywords = "Biomarkers, Chemokines, Community-acquired pneumonia, Cytokines, Inflammatory response, Mortality, Neutrophil functional responses, Outcome, Pneumococcal bacteremia, Pneumonia severity, Streptococcus pneumoniae",
author = "Bordon, {J. M.} and R. Fernandez-Botran and Wiemken, {T. L.} and P. Peyrani and Uriarte, {S. M.} and Arnold, {F. W.} and L. Rodriquez-Hernandez and Rane, {M. J.} and Kelley, {R. R.} and Binford, {L. E.} and S. Uppatla and R. Cavallazzi and F. Blasi and S. Aliberti and Marcos Restrepo and S. Fazeli and A. Mathur and M. Rahmani and K. Ayesu and J. Ramirez",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s15010-015-0837-z",
language = "English (US)",
volume = "43",
pages = "729--738",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel",
number = "6",

}

TY - JOUR

T1 - Bacteremic pneumococcal pneumonia

T2 - clinical outcomes and preliminary results of inflammatory response

AU - Bordon, J. M.

AU - Fernandez-Botran, R.

AU - Wiemken, T. L.

AU - Peyrani, P.

AU - Uriarte, S. M.

AU - Arnold, F. W.

AU - Rodriquez-Hernandez, L.

AU - Rane, M. J.

AU - Kelley, R. R.

AU - Binford, L. E.

AU - Uppatla, S.

AU - Cavallazzi, R.

AU - Blasi, F.

AU - Aliberti, S.

AU - Restrepo, Marcos

AU - Fazeli, S.

AU - Mathur, A.

AU - Rahmani, M.

AU - Ayesu, K.

AU - Ramirez, J.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose: Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP. Methods: This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1rα, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups. Results: From 833 pneumococcal CAP patients, 394 patients (47 %) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 % CI 0.69–0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 % CI 1.06–2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p 

AB - Purpose: Further examination of clinical outcomes and inflammatory response of bacteremic pneumococcal community-acquired pneumonia (CAP) is of great interest to enhance the care of patients with pneumococcal CAP. Methods: This is a secondary analysis of the Community Acquired Pneumonia Organization (CAPO) to compare the time to clinical stability (TCS), length of hospital stay (LOS), and in-hospital mortality of hospitalized pneumococcal CAP patients with and without bacteremia. To measure the effect of bacteremia in pneumococcal CAP patients on outcomes, we modeled all-cause in-hospital mortality using a Poisson regression model, and TCS and LOS using Cox proportional hazards models. Adjusted multivariate regression models were also used to predict the probability of occurrence of each of the study outcomes. To investigate the inflammatory response, we measured the plasma levels of pro- and anti-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1rα, IL-6, IL-8, IL-10], inflammatory biomarkers [C-reactive protein (CRP), pro-calcitonin (PCT), and B-type natriuretic peptide (BNP)], and peripheral blood neutrophil responses in 10 patients, 4 bacteremic and 6 non-bacteremic pneumococcal CAP, upon admission and every other day during the first 6 days of hospitalization. Functional data were presented as median and standard error of the median (SEM); due to small number of samples no statistical comparisons were performed between groups. Results: From 833 pneumococcal CAP patients, 394 patients (47 %) were bacteremic. Bacteremic pneumococcal CAP were less likely to reach TCS with an adjusted hazard ratio (AHR) of 0.82 (95 % CI 0.69–0.97; p = 0.02) and had higher in-hospital mortality with an AHR of 1.63 (95 % CI 1.06–2.50, p = 0.026). Bacteremic pneumococcal CAP patients had a longer LOS than non-bacteremic pneumococcal CAP (p 

KW - Biomarkers

KW - Chemokines

KW - Community-acquired pneumonia

KW - Cytokines

KW - Inflammatory response

KW - Mortality

KW - Neutrophil functional responses

KW - Outcome

KW - Pneumococcal bacteremia

KW - Pneumonia severity

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84948120695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948120695&partnerID=8YFLogxK

U2 - 10.1007/s15010-015-0837-z

DO - 10.1007/s15010-015-0837-z

M3 - Article

VL - 43

SP - 729

EP - 738

JO - Infection

JF - Infection

SN - 0300-8126

IS - 6

ER -